Related Experiment Videos
First-fill medication discontinuations and nonadherence to antihypertensive therapy: an observational study
Charity D Evans1, Dean T Eurich, Alfred J Remillard
1College of Pharmacy & Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Insights
Nearly 20% of new antihypertensive medication users stop treatment after just one prescription. This high rate of first-fill discontinuations significantly contributes to overall medication nonadherence in hypertension management.
Area of Science:
- Cardiovascular Health
- Pharmacology
- Public Health
Background:
- Medication nonadherence is a major challenge in hypertension management.
- The impact of immediate discontinuations on antihypertensive (AHT) nonadherence is not well understood.
Purpose of the Study:
- To determine the proportion of new AHT users who discontinue therapy after a single dispensation.
- To identify predictors of these early discontinuations.
Main Methods:
- Retrospective cohort study using linked administrative data from Saskatchewan, Canada (1994-2002).
- Included patients aged ≥40 years initiating AHT therapy.
- Analyzed first-fill discontinuation rates and associated factors using multivariate regression.
Main Results:
- 52,039 patients were analyzed; 50% were nonadherent at 1 year.
- First-fill discontinuations accounted for 39.1% of nonadherence, affecting approximately 20% of all patients.
- Higher chronic disease scores and antidepressant use increased discontinuation risk; older age and certain co-medications decreased risk.
Conclusions:
- A significant portion of antihypertensive medication nonadherence stems from discontinuations after the initial prescription.
- Understanding first-fill discontinuation predictors is crucial for improving hypertension management.
Background:
Medication nonadherence is a barrier to successfully managing hypertension, but little is known about the contribution that immediate discontinuations have on antihypertensive (AHT) nonadherence. The purpose of this study was to determine the proportion of new AHT users who discontinue after a single dispensation, and to examine potential predictors of these discontinuations.
Methods:
This retrospective cohort study utilizing linked administrative data from Saskatchewan, Canada. Subjects were ≥40 years of age and received a new AHT between 1994-2002. The primary end point was the proportion of subjects who discontinued their AHT after the first dispensation (first-fill discontinuation). The proportion of nonadherence attributed to first-fill discontinuations was then calculated. Multivariate regression identified factors associated with first-fill discontinuations.
Results:
52,039 subjects were included in the analyses. Mean age was 59.4 (s.d. 12.5) years, and 42% were male. Overall, 25,812/52,039 (50%) subjects were nonadherent at 1 year; first-fill discontinuations accounted for 39.1% (10,081/25,812) of this nonadherence. Approximately 20% (10,081/52,039) of all subjects discontinued all AHT therapy after the first fill. A higher chronic disease score (adjusted odds ratio (OR) 1.09, 95% confidence interval (CI) 1.08-1.11) and antidepressant medication usage during the observation year (adjusted OR 1.17, 95% CI 1.09-1.26) was associated with increased risk for first-fill discontinuations. Older age, starting AHT therapy after 1994, frequent physician visits, or use of a statin, acetylsalicylic acid, warfarin or antihyperglycemic during the observation year was associated with a lower risk for first-fill discontinuations.
Conclusion:
A substantial proportion of nonadherence to AHT medications is due to discontinuations after only a single dispensation.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension III: Clinical Manifestations and Diagnostic Studies
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Drug Therapy
Antianxiety Medications
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System